ライフサイエンスコーパス: serotype

1 ldren with immunity to just one dengue virus serotype.

2 oxin produced by a non-typhoidal Salmonellae serotype.

3 lso quantified the genetic diversity of each serotype.

4 Positive samples were molecular serotyped.

5 rwent culture for pneumococci; isolates were serotyped.

6 r use has increased infections by nonvaccine serotypes.

7 vaccine (PCV13) and the remaining non-PCV13 serotypes.

8 All IPD isolates were vaccine serotypes.

9 ued characterization of these alternative Ad serotypes.

10 protection upon challenge with invasive GAS serotypes.

11 he inhibitor's inefficacy against other DENV serotypes.

12 roximately 10%, and unveiled a large pool of serotypes.

13 h fIPV im was noninferior to fIPV id for all serotypes.

14 al carriage and disease due to PCV13-covered serotypes.

15 otently suppresses DENV-2 but not other DENV serotypes.

16 tration >=1.3 mug/mL for 70% of the measured serotypes.

17 CV7-targeted serotypes than the 6 PCV13-only serotypes.

18 umococcal pneumonia when infected with other serotypes.

19 re highly concordant in identifying dominant serotypes.

20 for recombination and emergence of novel IBV serotypes.

21 evel, overall and for each of the 10 leading serotypes.

22 P2C1 decreases transduction by different AAV serotypes.

23 evelopment is hampered by the high number of serotypes.

24 tial OPA responses were elicited against all serotypes.

25 isting AAV-binding antibodies against the 11 serotypes.

26 emain stable owing to replacement by non-PCV serotypes.

27 ere processed for pneumococcal isolation and serotyping.

28 sed VT detection by 31.5% over that by latex serotyping.

29 The capsule polymer of App serotype 1 (App1) consists of [4)-GlcNAc-beta(1,6)-Gal-a

30 s to and cross-neutralizes some dengue virus serotype 1 (DENV1) strains, with genotype-dependent inhi

31 incidence was 3-fold higher, amplified by a serotype 1 epidemic in 2011.

32 revalent in sub-Saharan Africa, pneumococcal serotype 1 is atypical in that it is rarely found as a n

33 Streptococcus pneumoniae serotype 1 is the predominant cause of invasive pneumoco

34 nd ST615 are representative of the two major serotype 1 lineages A and C, respectively.

35 Serotype 1 produces large quantities of pneumolysin, whi

36 xplanation for the increased invasiveness of serotype 1.

37 hildren <5 years was significantly lower for serotypes 1 (incidence rate ratio [IRR], 0.03 [95% CI, 0

38 of the 5 campaigns delivering bivalent OPV (serotypes 1 and 3) conducted during September 2017-April

39 ether immune interactions among dengue virus serotypes 1 to 4 (DENV1 to -4) extend to the closely rel

40 of PIV-associated pneumonia among individual serotypes 1, 2, and 3 and among all PIV infections with

41 , respectively; and (D) 100%, 100%, 100% for serotypes 1, 2, and 3, respectively.

42 98.7% (92.7-99.9), and 90.5% (81.5-96.1) for serotypes 1, 2, and 3, respectively; (B) 97.2% (90.3-99.

43 .2% (90.3-99.7), 100%, 95.8% (88.3-99.1) for serotypes 1, 2, and 3, respectively; (C) 89.3% (71.8-97.

44 7), 92.9% (76.5-99.1), 82.1% (63.1-93.9) for serotypes 1, 2, and 3, respectively; and (D) 100%, 100%,

45 ibed a UAD assay to detect the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,

46 ted with severe bacteraemic pneumonia during serotype-1 (ST217) infection.

47 a sonnei O-antigen, Streptococcus pneumoniae serotype 12F, and Staphylococcus aureus types 5 and 8 ca

48 st-vaccination as there was pre-vaccination (serotype 14) or post-PCV7 (serotype 19A), suggesting tha

49 PCV13 has reduced serotype 19A carriage among vaccinated children.

50 pre-vaccination (serotype 14) or post-PCV7 (serotype 19A), suggesting that future vaccines with addi

51 hedral viral capsids: Adeno Associated Virus serotype 2 (AAV2) and Minute Virus of Mice (MVM), both T

52 ase (IPD) caused by Streptococcus pneumoniae serotype 2 (Sp2) is infrequent.

53 The withdrawal of the serotype 2 component of oral poliovirus vaccine (OPV2) w

54 Streptococcus suis serotype 2 is an important bacterial pathogen of swine a

55 4% to 99.8%) for vaccine and vaccine-derived serotype 2 poliovirus, and 88.3% (81.2% to 93.5%) and 93

56 DPV2 emergence and secure eradication of all serotype 2 poliovirus.

57 By using the serotype 2 strain D39, we transcriptionally fused the fi

58 irus for more than 20 years, transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associ

59 Although there have been no cases of serotype 2 wild poliovirus for more than 20 years, trans

60 cal translation in an adeno-associated virus serotype 2-mediated human aromatic L-amino acid decarbox

61 tive efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the

62 A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized

63 , we thought to evaluate avian paramyxovirus serotype 3 (APMV-3) strain Netherlands as a safe vaccine

64 but not 19A (IRR, 0.6 [95% CI, .3-1.12]) or serotype 3 (IRR, 2.3 [95% CI, .86-6.15]) in the late PCV

65 We found no impact of PCV13 on serotype 3 carriage or disease, and emergence of non-PCV

66 es by PCV13 serotypes, showing a decrease of serotype 3 when PCV13 was used.

67 pecific (TS) antibodies, especially for DENV serotype 3, which has only one well-studied, strongly ne

68 ntrol IPD cases by PCV13 serotypes including serotype 3.

69 from an invasive-disease-causing isolate of serotype 4 (TIGR4).

70 except for pertussis toxin and pneumococcal serotypes 4 and 19F after the primary series and booster

71 uman adenovirus, human adenovirus subgroup C serotype 5 (HAd5), when systemically administered, trigg

72 ed an arbitrary threshold (8 ug/mL) for each serotype 60 days postdose 2 vs 36%-56% postdose 1 in pre

73 r than serotype 9N (67 [53-80] years), PCV13 serotypes (68 [52-81] years), and remaining non-PCV13 se

74 Here, we show that a S. pneumoniae serotype 6B ST90 strain, which does not cause disease in

75 (68 [52-81] years), and remaining non-PCV13 serotypes (70 [53-82] years).

76 were responsible for 20.1% (n = 4033), while serotype 8 (3881/20 108 [19.3%]), 12F (2365/20 108 [11.8

77 by herd protection although the increase of serotype 8 in adults is worrisome.

78 dian age (interquartile range) at IPD due to serotypes 8 (59 [45-72] years) and 12F (56 [41-70] years

79 Serotypes 8 and 12F were more likely to cause IPD in you

80 significant rises in IPD incidence were for serotypes 8, 12F, and 24F.

81 nvasive pneumococcal disease (IPD) caused by serotypes 8, 12F, and 9N; their clinical characteristics

82 Currently, NVT serotypes 8, 9N, 15A and 23B are increasing in the count

83 esent in the 13-valent PCV (PCV13) and 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) is curre

84 antigen (HLA)-A2.1 by adeno-associated virus serotype 9 (AAV9) vectors.

85 ly delivered an adeno-associated virus (AAV) serotype 9 carrying the human GBA gene under control of

86 t, mice injected with adeno-associated virus serotype 9 encoding PDE4B (10(12) viral particles/mouse)

87 Similarly, adeno-associated virus serotype 9 encoding PDE4B slowed contractile deteriorati

88 s throughout the brain more efficiently than serotype 9.

89 ic administration via adeno-associated virus serotype 9.

90 s) and 12F (56 [41-70] years) was lower than serotype 9N (67 [53-80] years), PCV13 serotypes (68 [52-

91 dividuals and less likely to be fatal, while serotype 9N affected older adults with comorbidities and

92 nce of invasive disease due to H. influenzae serotype a (Hia) increased an average of 13% annually fr

93 r suspected exposure to botulinum neurotoxin serotypes A-G in adults and pediatric patients.

94 hogen or serotype specific, with isolates of serotype A1, A2, A6 and A12 being capable of colonising

95 that, although antibodies binding known AAV serotypes (AAV1 to AAV11) are prevalent in cats living i

96 iodistribution of AAV2.retro with its parent serotype, AAV2, in adult macaques following delivery int

97 HAdV F40/41 serotypes account for the majority of HAdV-positive gast

98 From 2013 to 2014, non-PCV13 serotypes accounted for 80% of IPD.

99 AAV8, AAV9, and AAV10 serotypes all transduced thymocyte subsets after in situ

100 Antibody levels to PPV23 serotypes also increased postvaccination (P < .001).

101 cci via the relative risk of detecting these serotypes among vaccinated versus unvaccinated controls.

102 ffected by antigenic variability within each serotype and mismatching between test reagents.

103 Protection against PCV13-serotype and PCV7-serotype CAAP was 67.0% (-424.3-100.0%

104 .0%) and 91.4% (-191.4-100.0%) against PCV13-serotype and PCV7-serotype CAAP.

105 tailored to the individual FMD virus (FMDV) serotype and their sensitivity may be affected by antige

106 Diversity also varied markedly by serotype and was associated with the presence of specifi

107 and genotypic methods to detect pneumococcal serotypes and antimicrobial resistance.

108 verity of infection among the individual PIV serotypes and between PIV and other pathogens in patient

109 CV driven by decreasing frequency of vaccine serotypes and increasing frequency of few NVTs mainly in

110 erotyping is accurate in identifying vaccine serotypes and requires the least expertise and resources

111 ya children had immunity gaps to all 3 polio serotypes and should be targeted by future campaigns and

112 lyclonal memory B cells (MBCs) to the 4 DENV serotypes and ZIKV during DENV infection is not fully un

113 fic total IPD, PCV13 non-7-valent PCV (PCV7) serotypes, and PnCAP by Indigenous status.

114 ic mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy

115 d by culture, qPCR, whole genome sequencing, serotyping, and reverse transcription qPCR.

116 For each serotype, anti-GBS geometric mean concentrations (GMCs)

117 Certain pairs of serotypes are more likely to co-occur on the same geneti

118 emonstrates that both HSV and individual AAV serotypes are non-randomly distributed among neuronal su

119 cquired salmonellosis and leading Salmonella serotypes are poorly understood.

120 for investigating the importance of vaccine serotypes at low relative abundances in transmission and

121 that persistently replicate HBV (genotype D, serotype ayw)-either from a transgene or after infection

122 effective responses to each of the four DENV serotypes because of differences in the replication effi

123 design, we compared the frequencies of HAdV serotypes between children with >=3 episodes of vomiting

124 family of bacterial toxins with seven major serotypes (BoNT/A-G).

125 he hemoglobin-dependent response in multiple serotypes, but not with other host proteins, free iron,

126 Nasopharyngeal pneumococci were molecular-serotyped by microarray.

127 Isolates from sterile sites were serotyped by real-time polymerase chain reaction.

128 Identifying Streptococcus pneumoniae serotypes by urinary antigen detection (UAD) assay is th

129 For molecular serotyping by microarray, we used the BUGS Bioscience Se

130 attributed to the identified serotype; when serotypes C1, C2, C5, and C6 were detected, they were re

131 Protection against PCV13-serotype and PCV7-serotype CAAP was 67.0% (-424.3-100.0%) and 67.7% (-1962

132 91.4-100.0%) against PCV13-serotype and PCV7-serotype CAAP.

133 While members of this serotype can acquire resistance to antimicrobials, the t

134 ion of certain adeno-associated virus vector serotypes can cross the blood-brain barrier to deliver a

135 Three serotype capsids, AAV1, AAV2, and AAV9, have been approv

136 may confer lower protection against vaccine-serotype carriage during and beyond the first year of li

137 ructure, and microarray, which adds multiple-serotype carriage, should be considered at regional refe

138 nization criterion for studying pneumococcal serotypes carried without isolating bacteria.

139 lysaccharide components and the frequency of serotype co-occurrence and diversity.

140 2% (95% CI, 33-83%) protection against PCV13-serotype colonization at ages 13-24 months and 25-59 mon

141 Modelling of dominant serotype colonization data produced plausible VE estimat

142 nt PCV (PCV13) effectiveness against vaccine-serotype colonization in a modified case-control framewo

143 e of differing PCV schedules against vaccine-serotype colonization in children.

144 tiveness of 2p+1b PCV dosing against vaccine-serotype colonization.

145 delivery of meganucleases using a triple AAV serotype combination results in the greatest decrease in

146 re subjected to bacteriological examination, serotyping, congo-red binding assay, antibiogram-testing

147 coccal disease worldwide; however, expanding serotype coverage may further reduce disease burden.

148 IPD cases by additional serotypes covered by PPV23 increased from 20% in 2009 to

149 ralizing antibody titers for the four dengue serotypes (DENV) up to Month 36 in part 1, and symptomat

150 Streptococcus pneumoniae (Pnc) serotypes differ in invasive potential.

151 The adjusted VE (aVE) estimate against PPV23 serotype disease was 24% (95% CI 5%-40%, p = 0.02).

152 riage or disease, and emergence of non-PCV13-serotype disease.

153 s via intravenous delivery; however, natural serotypes display a finite set of tropisms.

154 Accurate assessment of the serotype distribution associated with pneumococcal colon

155 structure, within-lineage serotype dynamics, serotype diversity, and frequency of antibiotic resistan

156 Reactivity to the infecting serotype dominated the total MBC response.

157 nges in population structure, within-lineage serotype dynamics, serotype diversity, and frequency of

158 Pneumococcus is a diverse pathogen, with >90 serotypes, each of which has a distinct polysaccharide c

159 Although there are several distinct PIV serotypes, few studies have compared the clinical charac

160 dence in 2013-2014 and 2007-2008, by age and serotype group (PCV13, PPSV23-unique, or nonvaccine type

161 The E. coli K15 serotype has been identified as both an enterotoxigenic

162 as it is highly conserved across influenza A serotypes, has a low mutation rate, and is essential for

163 d by the human leukocyte antigen with the A2 serotype (HLA-A2) that has been observed in about 35% of

164 endpoints (efficacy by baseline serostatus, serotype, hospitalised dengue, and severe dengue) in the

165 Serotype hu.11 transduced fewer cells in the brain than

166 ectron microscopy (cryo-EM) structure of the serotype I FIPV spike (S) protein, which is responsible

167 ion of disease attributed to individual HAdV serotypes (i.e., attributable fraction).

168 (10 serotype Ia and 11 serotype III), and 84 serotype Ia and 105 serotype III noncolonized matched co

169 cto-vaginally colonized matched controls (10 serotype Ia and 11 serotype III), and 84 serotype Ia and

170 k samples were available for 31 LOD cases (8 serotype Ia and 23 serotype III), 21 recto-vaginally col

171 re 90% reductions in the risks of developing serotypes Ia and III LOD with sIgA concentrations >=0.14

172 CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III), administered to nonpregnant women

173 (GMC) were lower in cases than controls for serotype-Ia (0.05 vs. 0.50ug/ml; p=0.004) and III (0.20

174 threshold associated with a reduced risk for serotype-Ia and III IGbsD identified on infant sera supp

175 l were associated with 90% risk reduction of serotype-Ia and III IGbsD, respectively.

176 he association between naturally-derived GBS serotype-Ia and III IgG and risk reduction of IGbsD in i

177 isk reduction was >=2.31 and >=3.41ug/ml for serotype-Ia and III, respectively.

178 Mothers colonized vaginally with serotype-Ia or III at birth, and their healthy infants w

179 11 serotype III), and 84 serotype Ia and 105 serotype III noncolonized matched controls.

180 lable for 31 LOD cases (8 serotype Ia and 23 serotype III), 21 recto-vaginally colonized matched cont

181 ized matched controls (10 serotype Ia and 11 serotype III), and 84 serotype Ia and 105 serotype III n

182 , the UAD-2 assay identified a S. pneumoniae serotype in 3.72% of nonbacteremic CAP cases obtained fr

183 ial for therapeutic application of the hu.32 serotype in a gyrencephalic brain of larger mammals, a h

184 is finding was replicated by analysis of HLA serotypes in 338 individuals with membranoproliferative

185 xisting humoral immunity against various AAV serotypes in cats is still limited.

186 ically confirmed CAP caused by S. pneumoniae serotypes in hospitalized US adults.

187 tinguish among infection with individual PIV serotypes in patients hospitalized with community acquir

188 etiological role of human adenovirus (HAdV) serotypes in pediatric gastroenteritis.

189 ed case studies, namely, outbreaks of dengue serotypes in Puerto Rico and a rapidly unfolding outbrea

190 es as measured by OPA were robust for all 20 serotypes included in the vaccine, with geometric mean f

191 t adults seems to control IPD cases by PCV13 serotypes including serotype 3.

192 effective against multiple human astrovirus serotypes, including clinical isolates.

193 ths postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all anti

194 rotypes resembles protection against vaccine-serotype invasive pneumococcal disease.

195 With all serotyped IPD isolates covered by pneumococcal vaccines,

196 However, the emergence of non-vaccine serotypes is of great concern worldwide.

197 Latex serotyping is accurate in identifying vaccine serotypes

198 15 to 2017-18, including 20 108 (93.1%) with serotyped isolates and 17 450 (86.8%) with completed que

199 ship was consistent by race/ethnicity and by serotype, it was not present in 5 FoodNet sites or among

200 charide of a dominated Klebsiella pneumoniae serotype K2 is difficult to synthesize chemically due to

201 The capacity of North-East Asian serotype M12 (emm12) Streptococcus pyogenes (group A Str

202 To conclude, all three serotyping methods were highly concordant in identifying

203 the lack of effective vaccines against some serotypes necessitates novel measures to control ERM.

204 aja Saponin was evaluated against Salmonella serotypes Newport, Oranienburg and Typhimurium.

205 declined, partial replacement by non-vaccine serotypes (NVT) was observed following widespread vaccin

206 otypes (VT) and the emergence of non-vaccine serotypes (NVT).

207 There was an increase of nonvaccine serotypes (NVTs)-namely 7C, 15B/C, and 23A-in children <

208 MPORTANCE Among the seven serotypes of FMDV, serotype O FMDV have the broadest distribution worldwide

209 It was shown that antibodies target one serotype of viruses but only subneutralize another, lead

210 minance worldwide.IMPORTANCE Among the seven serotypes of FMDV, serotype O FMDV have the broadest dis

211 he highest genetic diversity among all seven serotypes of FMDV, we propose that the lower polymerase

212 Molecular serotyping of the 450 generated genomes identified a div

213 wer for F40/41 serotypes than for non-F40/41 serotypes (P < 0.001).

214 Certain serotype pairs are more likely to occur on the same gene

215 evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and

216 of green fluorescence protein via AAV vector serotype PHP.B in adult wild-type male mice transduced n

217 4.93) greater odds, respectively, of vaccine-serotype pneumococcal colonization at ages 13-24 months.

218 ococcal pneumonia and a control as non-PPV23 serotype pneumococcal pneumonia or nonpneumococcal pneum

219 pediatric pneumonia attributable to vaccine-serotype pneumococci remains unknown.

220 tection against CAAP attributable to vaccine-serotype pneumococci via the joint reduction in risks of

221 erred protection against carriage of vaccine-serotype pneumococci via the relative risk of detecting

222 alent pneumococcal conjugate vaccine (PCV13) serotype pneumonia (n = 417 cases, 43.7% vaccinated) was

223 modulate dengue disease severity like a DENV serotype poses challenges to development of dengue and Z

224 Serotype positivity was based on cutoffs determined by n

225 serotypes, there has not been a dominant IPD serotype post-vaccination as there was pre-vaccination (

226 mics of the residual VTs and replacement NVT serotypes post-PCV.

227 aining capsular polysaccharide conjugates of serotypes present in the 13-valent PCV (PCV13) and 7 new

228 this unique response is specific to the Ad4 serotype rather than the transgene expressed.

229 Significant carriage of these serotypes remains in all age groups.

230 oral streptococcal cps, it may increase its serotype repertoire.

231 IPD incidence varied internationally due to serotype replacement.

232 ttributable to vaccine-targeted pneumococcal serotypes resembles protection against vaccine-serotype

233 aluated the concordance between pneumococcal serotyping results by latex agglutination, whole-genome

234 Twenty-one serotypes/serogroups were detected by qPCR compared to 1

235 A small number of other serotypes share this property, three of which were teste

236 obulin G (IgG) antibody titers against the 7 serotypes shared by PCV7, PCV13, and PSV23.

237 and 11% respectively the IPD cases by PCV13 serotypes, showing a decrease of serotype 3 when PCV13 w

238 O antigen structures are serotype specific and form extended cell surface barrier

239 at colonisation was not strictly pathogen or serotype specific, with isolates of serotype A1, A2, A6

240 response to DENV after primary infection is serotype specific.

241 Serotype-specific (Ia/Ib/III) anti-GBS antibodies were m

242 mation on the association of breast milk GBS serotype-specific capsular antibodies and risks for inva

243 Strain- and serotype-specific differences influence the ability of i

244 KV antibody development suggesting that this serotype-specific immune profile is capsid-dependent.

245 These results highlight the serotype-specific immune profiles elicited by different

246 Here, we analyzed ASFV serotype-specific locus (C-type lectin (EP153R) and CD2v

247 rt the significance of recombinations in the serotype-specific locus.

248 capturing pneumococcal polysaccharides with serotype-specific monoclonal antibodies, using Luminex t

249 TDV results in essentially equivalent dengue serotype-specific NAb titers as the currently used sched

250 er pairs from previous studies, a search for serotype-specific P fimbriae papA alleles, and a BLASTn

251 lowed by PPSV23 in IBD patients by measuring serotype-specific pneumococcal immunoglobulin G antibody

252 A case was defined as PPV23 serotype-specific pneumococcal pneumonia and a control a

253 rved across Salmonella and confer broad, non-serotype-specific protection, are also discussed.

254 lar polysaccharide (CPS) offer S. pneumoniae serotype-specific protection.

255 erm febrile surveillance to detect dengue by serotype-specific RT-PCR.

256 for virologically confirmed dengue (VCD) by serotype-specific RT-PCR.

257 vide an explanation for observed strain- and serotype-specific variability in RocA function.

258 the same genetic background as a results of serotype switching, but the drivers of these patterns ar

259 al varied substantially among the Salmonella serotypes tested.

260 dy levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite pre

261 Among cases, Ct values were lower for F40/41 serotypes than for non-F40/41 serotypes (P < 0.001).

262 3-conferred protection against PCV7-targeted serotypes than the 6 PCV13-only serotypes.

263 Despite its relevance as a disease-causing serotype, the associated capsular polysaccharide remains

264 Despite these common emerging serotypes, there has not been a dominant IPD serotype po

265 to remain stable post-PCV due to replacement serotypes, there was no change in diversity of NVTs.

266 neutralising geometric mean titres for each serotype to month 48 assessed in the per-protocol immuno

267 Newport was the most (p < 0.05) susceptible serotype to PA emulsions.

268 of intrathymic adeno-associated virus (AAV) serotypes to transduce thymocyte subsets and correct the

269 We reviewed Salmonella enterica serotype Typhi infections reported to the Centers for Di

270 rial infection caused by Salmonella enterica serotypes Typhi and Paratyphi A, frequently presents as

271 Salmonella enterica serotype Typhimurium (S. Typhimurium) boasts a broad hos

272 Additionally, Salmonella serotypes Typhimurium and Newport also formed floccular

273 y interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and transmission.

274 By detecting additional vaccine serotype (VT) pneumococci carried at low relative abunda

275 cci and 39.2% (95% CI 26.7-46.1) for vaccine serotype (VT) pneumococci.

276 is threatened by the persistence of vaccine serotypes (VT) and the emergence of non-vaccine serotype

277 occal disease (IPD) incidence due to vaccine serotypes (VT) has declined, partial replacement by non-

278 s of age, frequency and diversity of vaccine serotypes (VTs) decreased significantly post-PCV, but no

279 Vaccine efficacy varied by serotype, warranting continued follow-up to assess longe

280 s, the proportion of pneumonias with a UAD-2 serotype was 4.33%.

281 Clearance of VT serotypes was consistent across different genetic backgr

282 e breadth of MBC responses against different serotypes was greater after secondary DENV infection.

283 Replication of RV-A serotypes was strictly dependent on STING, whereas RV-B

284 model to achieve nasal colonization with 6B serotype, we investigated the effect of Spn colonization

285 The most common pneumococcal serotypes were 3 (4 episodes), 35B, 9N, 38, and 15C (eac

286 , clinical pneumococcal strains of different serotypes were also able to develop natural competence d

287 Cases due to emerging serotypes were compared with those included in the 13-va

288 Pneumococcal serotypes were identified from urine samples using a mul

289 Only seven of the approximately 100 serotypes were initially included in the pneumococcal po

290 AAV serotypes were injected intrathymically into wild-type m

291 as strictly dependent on STING, whereas RV-B serotypes were notably less dependent.

292 PCV13 serotypes were responsible for 20.1% (n = 4033), while s

293 mptoms could be attributed to the identified serotype; when serotypes C1, C2, C5, and C6 were detecte

294 ly immunogenic and conserved epitopes across serotypes, which may impact design of new universal T-ce

295 elicited antibody responses against all four serotypes, which persisted to 48 months post-vaccination

296 gesting that future vaccines with additional serotypes will be less effective at targeting and reduci

297 Conversely, serotypes with lower disease potential (15A, 15BC, 16F,

298 ples and/or rectal swabs underwent molecular serotyping with cycle threshold (Ct) values provided by

299 19 highly conserved epitopes across the four serotypes within the immunogenic regions of NS3, NS4B an

300 bution of DENV genome sequences across the 4 serotypes worldwide.